About DREAMM-7 The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with BorDex compared to a combination of daratumumab and BorDex in patients with ...
Of note, in the CASTOR trial, median OS with DVd was 49.6 months in patients with a median of 2 prior lines of therapy. We will present the results from the second planned interim analysis of DREAMM-7, with an approximate 3.3 years of follow-up; this will provide further insight on ...
In Part 2, clinical activity was demonstrated with both combination treatments investigated; all three patients (100%) treated with belantamab mafodotin plus bortezomib and dexamethasone in Arm A achieved an overall response. These findings align with those from the recent DREAMM-7 trial that ...
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7). ClinicalTrials.gov. Updated December 13, 2023. Accessed June...
Of note, in the CASTOR trial, median OS with DVd was 49.6 months in patients with a median of 2 prior lines of therapy. We will present the results from the second planned interim analysis of DREAMM-7, with an approximate 3.3 years of follow-up; this will provide further insight on ...
The DREAMM-8 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with PomDex compared to a combination of bortezomib and PomDex in patients with relapsed/refractory multiple myeloma previously treated with...
EP: 3.DREAMM-2 Trial Efficacy Data and Recent FDA Approval EP: 4.DREAMM-2 Trial Regimen Safety Profile EP: 5.Management of Ocular Events From DREAMM-2 Regimen EP: 6.DREAMM-2 Trial Regimen: Safety Updates and Dose Delay EP: 7.Next Steps for Use of Belantamab in Clinical Practice EP...
the only other clinical trial designed to prospectively evaluate an anti-myeloma treatment (combination selinexor plus dexamethasone) in patients refractory to at least one PI, one immunomodulatory agent, and daratumumab (as in DREAMM-2), in which an ORR of 26% was reported7. The STORM study ...
DREAMM-2 Trial Regimen: Safety Updates and Dose Delay EP: 7.Next Steps for Use of Belantamab in Clinical Practice EP: 8.Ongoing Approaches Toward Targeting BCMA EP: 9.Influencing Factors to Initially Targeting BCMA in MM Asim V. Farooq, MD: The poster that was presented at the ...
December 5, 2020 - The addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.